| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514439000 | Plural hetero atoms in the hetero ring | 79 |
| 20100029745 | DERIVATIVES OF SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONES AND OF 3-PHENYL-1-(PHENYLFURANYL) PROPAN-1-ONES, PREPARATION AND USE - The present invention relates to compounds derived from substituted 3-phenyl-1-(thien-2-yl)propan-1-ones, pharmaceutical compositions comprising them as well as their therapeutic applications, notably in the field of human and animal health. | 02-04-2010 |
| 514440000 | Only two ring sulfurs in the hetero ring | 78 |
| 20080214653 | Methods and Compositions for the Prevention and Treatment of Kindney Disease - The invention provides compositions for preventing or treating kidney disease and improving kidney function comprising at least two ingredients selected from the group consisting of antioxidants and mitochondrial cofactors in amounts sufficient for preventing or treating kidney disease or for improving kidney function and methods for preventing and treating kidney disease or improving kidney function comprising administering such compositions to an animal susceptible to or suffering from kidney disease or impaired kidney function. In a preferred embodiment, the composition is admixed with one or more food ingredients to produce a food composition useful for preventing or treating kidney disease and improving kidney function, particularly in senior animals. | 09-04-2008 |
| 20080262077 | PHARMACEUTICAL FORMULATIONS CONTAINING LIPOIC ACID DERIVATIVES - Pharmaceutical formulations containing lipoic acid derivatives are made. | 10-23-2008 |
| 20090054513 | METHOD OF MANAGING BLOOD GLUCOSE LEVELS, INSULIN LEVELS AND/OR INSULIN RECEPTOR FUNCTIONALITY IN INDIVIDUALS WITH DIABETES, POLYCYSTIC OVARIAN SYNDROME AND/OR ALZHEIMER'S DISEASE - A combination of constituents for oral administration by women with polycystic ovarian syndrome includes α-lipoic acid, linolenic acid complex, biotin, and coenzyme Q-10. A preferred method of manufacture is by separate microencapsulation of one or more of the components followed by encapsulation of the individual components, for oral administration. Other methods of delivery include packaging in impermeable, disposable packets and mixing the formulations with food or a cold liquid. A combination of constituents for administration by either men or women to encourage increase in brain insulin levels and/or brain insulin receptor functionality also includes α-lipoic acid, linolenic acid complex, biotin, and coenzyme Q-10. | 02-26-2009 |
| 20090124683 | MERCAPTAN AND SELENO-MERCAPTAN COMPOUNDS AND METHODS OF USING THEM - Novel mercaptan compounds, particularly those including a photolabile protecting group, are described as well as methods of using the compounds for the prevention and treatment of ocular damage and disease. | 05-14-2009 |
| 20090149529 | Antioxidant-Containing Food Composition For Use In Enhancing Antiviral Immunity In Companion Animals - The invention encompasses compositions for enhancing the ability of a companion animal to resist and/or overcome viral infections. The compositions of the invention include an amount of lipoic acid that is effective in enhancing the antiviral immunity of a companion animal. | 06-11-2009 |
| 20090156658 | Antioxidant-Containing Food Composition For Use In Inhibiting Histamine Pathways In Companion Animals - The invention encompasses compositions for inhibiting histamine release pathways in a companion animal, for example, felines and in treating or preventing idiopathic cystitis or interstitial cystitis. The compositions of the invention include an amount of lipoic acid that is effective in inhibiting histamine release pathways in a companion animal, for example, felines and in treating or preventing idiopathic cystitis or interstitial cystitis. | 06-18-2009 |
| 20090163573 | COMPOSITIONS AND METHODS FOR ENHANCING PROTEIN ACCRETION IN SKELETAL MUSCLE - A nutritional composition comprising at least an effective amount of geranylgeranylacetone or derivative of geranygeranylacetone and an effective amount of glutamine or derivative of glutamine, wherein the ingredients act substantially simultaneously to increase protein synthesis and inhibit protein degradation in skeletal muscle, via enhanced expression of heat shock proteins in cells, particularly heat shock protein 72. A method of same is also provided. | 06-25-2009 |
| 20090176864 | Methods For Improving Hepatic and Immune Function In An Animal - The invention encompasses compositions and methods for improving animal health and in certain embodiments to compositions and methods for improving hepatic and immune function in aged felines. | 07-09-2009 |
| 20090233995 | Use of drug combinations for treating insulin resistance - The present invention provides pharmaceutical compositions comprising: (a) a modulator of hepatic parasympathetic tone, (b) at least one diabetes drug, and (c) a pharmaceutically acceptable carrier. The present invention includes methods for the treatment and/or prevention of insulin resistance, type 2 diabetes, impaired glucose intolerance, and other associated disorders with pharmaceutical compositions described herein. The invention also provides for a kit comprising a pharmaceutical composition and instructions for its use. | 09-17-2009 |
| 20090239941 | AMINO ACID DERIVATIVES - Compounds of formula (I) are active as dopaminergic compounds or as compounds which or as compounds which diminish the symptoms of dopamine deficiency: wherein: R | 09-24-2009 |
| 20090298923 | Salicylate Conjugates Useful for Treating Metabolic Disorders - The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants. | 12-03-2009 |
| 20090312404 | Cleavable Carnitine Compound - The invention includes novel compounds, including but not limited to formula A and formula B, and an improved delivery method. These compounds and methods are useful in preventing or treating diseases or conditions associated with or caused by the presence of free radicals, and are useful for increasing cellular metabolism while simultaneously alleviating the resultant increase in oxidative stress. Specifically, a carnitine is bound to a lipoic acid derivative or to dihydrolipoic acid or its derivatives using a hydrolysable linker to form a single compound. | 12-17-2009 |
| 20100022629 | Dietary Methods and Compositions for Enhancing Metabolism and Reducing Reactive Oxygen Species - This invention relates to methods comprising administering to a subject a dietary composition for modifying cellular metabolism, metabolic production of reactive oxygen species and the resulting level of reactive oxygen species. The invention is drawn to a method comprising a combination of carnitine, lipoic acid and polyphenol, which has the effect of enhancing metabolism and reducing oxygen species at the same time. The invention is also drawn to a method of oral administration of carnitine, lipoic acid and polyphenol to a mammalian host, at an effective dose necessary to affect enhanced metabolic processes and reduced oxygen species in animals including humans. | 01-28-2010 |
| 20100056613 | SPIROQUINONE COMPOUND AND PHARMACEUTICAL COMPOSITION - A novel spiroquinone derivative having a high ABCA1 stabilization effect and being useful for prophylactic and/or therapeutic agents for various diseases developing hypo-high density lipoproteinemia is obtained. The novel spiroquinone derivative is a compound represented by the following formula: | 03-04-2010 |
| 20100076064 | Methods For Improving Liver Clearance of Xenobiotic Substances In An Animal - A method for improving liver clearance of xenobiotic substances in an animal by feeding the animal lipoic acid in amounts of from about 10 mg to about 1000 mg per day. | 03-25-2010 |
| 20100099751 | Method of treating diabetes-related vascular complications - A method of treating diabetes-related vascular complications is provided. It has been found that a heightened state of oxidative stress, either acting alone or in concert with augmented apoptotic and inflammatory processes, contributes to diabetes-related vascular dysfunction. The method of treating diabetes-related vascular complications includes the treatment of diabetic patients with alpha-lipoic acid (LA) in order to mitigate the negative impact of diabetes-related vascular dysfunctions upon vascular homeostasis. The treatment method includes the step of administering to the patient a therapeutically effective dosage of alpha-lipoic acid. | 04-22-2010 |
| 20100160422 | HALOGEN-CONTAINING ORGANOSULFUR COMPOUND AND USE THEREOF - There is provided a halogen-containing organosulfur compound having an excellent controlling effect on arthropod pests represented by the formula (I): wherein, m represents 0, 1 or 2, n represents 0, 1 or 2, A represents optionally substituted C3-C7 cycloalkyl or optionally substituted C5-C7 cycloalkenyl group, Q represents a C1-C5 haloalkyl group containing at least one fluorine atom, or a fluorine atom, R | 06-24-2010 |
| 20100210716 | Process for Preparing an Alpha-Lipoic Acid/Cyclodextrin Complex and Product Prepared - The invention relates to a process for the preparation of a cyclodextrin/alpha-lipoic acid complex, wherein in a first step, an alpha-lipoic acid and a cyclodextrin are dissolved in an aqueous alkaline solution having a pH above pH 7, and in a second step an acid is added to lower the pH of the solution to a pH below pH 7. | 08-19-2010 |
| 20100234452 | Anti-Inflammatory and Antioxidant Conjugates Useful for Treating Metabolic Disorders - The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants. | 09-16-2010 |
| 20100292313 | COMPOSITIONS AND METHODS FOR TREATING ISCHEMIA AND ISCHEMIA-REPERFUSION INJURY - The present invention relates to compositions comprising a substantially pure compound represented by Structural Formula II: | 11-18-2010 |
| 20100298421 | DERIVATIVES OF TAXOL AND CLOSELY RELATED COMPOUNDS - A cytotoxic composition in which two moieties are conjugated covalently. A first moiety is a tax moiety, selected from the group consisting of taxanes, taxane derivatives, and or other closely relative compounds. A second moiety is an acid moiety selected from the group consisting of lipoic acid, acetylcysteine, compounds having an acidic group. | 11-25-2010 |
| 20100317725 | Choline Esters - Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage. | 12-16-2010 |
| 20110065781 | Alpha-LIPOIC ACID NANOPARTICLES AND METHODS FOR PREPARING THEREOF - Provision of a stable α-lipoic acid. A method for producing α-lipoic acid nanoparticles, the method comprising the steps of: preparing an aqueous dispersion liquid containing α-lipoic acid and a nonionic surfactant; adding a divalent metal salt into the aqueous dispersion liquid, wherein the divalent metal salt is a divalent metal halide, a divalent metal acetate or a divalent metal gluconate; and adding an alkali metal carbonate or an alkali metal phosphate into the aqueous dispersion liquid which has been added with the divalent metal salt, thereby forming α-lipoic acid nanoparticles. | 03-17-2011 |
| 20110082192 | LIPOIC ACID ACYLATED SALICYLATE DERIVATIVES AND THEIR USES - The invention relates to lipoic acid acylated salicylate derivatives; compositions comprising an effective amount of a lipoic acid acylated salicylate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a lipoic acid acylated salicylate derivative. | 04-07-2011 |
| 20110098347 | PHOSPHOROUS BINDER FOR TREATMENT OF KIDNEY DISEASE - The present invention relates to oral compositions which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The dietary supplements and pharmaceutical products and methods of the present invention are particularly useful in the treatment of hyperphosphatemia of chronic uremia and reducing serum phosphorus levels in patients requiring such therapy. | 04-28-2011 |
| 20110144188 | SALTS OF TRIMEBUTINE AND N-DESMETHYL TRIMEBUTINE - Unique salts of trimebutine and N-monodesmethyl trimebutine, and their corresponding stereoisomers, having improved analgesic properties useful in the treatment of visceral pain are provided. The salts of the present invention are particularly useful in the treatment of conditions characterized by abdominal pain, such as inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS), diabetic gastroparesis, and dyspepsia. | 06-16-2011 |
| 20110160294 | COMPOSITIONS AND METHODS FOR TREATING ISCHEMIA AND ISCHEMIA-REPERFUSION INJURY - The present invention relates to compositions comprising a substantially pure compound represented by Structural Formula I: | 06-30-2011 |
| 20110184054 | Alpha-lipoic acid concentrate - A water-free concentrate, consisting of ubiquinone Q | 07-28-2011 |
| 20110213021 | COMPOSITIONS AND METHODS FOR TREATING NOS-ASSOCIATED DISEASES - The disclosures herein provide lipoic acid salts, as well as polymorphs, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, transdermal administration, or injection. Such compositions may be used to treat NOS-associated diseases such as inflammatory diseases, metabolic diseases and neurodegenerative diseases. | 09-01-2011 |
| 20110213022 | STABLE, WATER-INSOLUBLE R-(+)-ALPHA-LIPOIC ACID SALT USEFUL FOR THE TREATMENT OF DIABETES MELLITUS AND ITS CO-MORBIDITIES - The present invention relates to oral nutritional and therapeutic products which are useful for preventing or treating compensated and decompensated insulin resistance and associated diseases and sequelae, or diabetes mellitus and its sequelae, complications, and co-morbidities, comprising magnesium R-(+)-alpha-lipoate. | 09-01-2011 |
| 20110218235 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF - A compound, composition, method of synthesizing and using the compound of formula 1 are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, and hydrates thereof. The compound may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral, topical, transmucosal, inhalation, targeted delivery and sustained release formulations. Such compositions may be used to treat hepatic and genetic disorders related to copper overload. | 09-08-2011 |
| 20110218236 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF - A compound, composition and method of making and using a compound of formula 1 are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, mesylates, hydrochloric salt, solvates and hydrates thereof. The compound may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral, topical, transmucosal, inhalation, targeted delivery and sustained release formulations. Such compositions may be used to treat metal accumulation in blood, organs and due to genetic complications. | 09-08-2011 |
| 20110218237 | COMPOUND AND COMPOSITION AND THEIR USES THEREOF - A compound, composition and method of making and using a compound of formula 1 are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, mesylates, hydrochloric salt, solvates and hydrates thereof. The compound may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral, topical, transmucosal, inhalation, targeted delivery and sustained release formulations. Such compositions may be used to treat metal accumulation in blood, organs and due to genetic complications. | 09-08-2011 |
| 20110218238 | COMPOUNDS, COMPOSITIONS, FORMULATIONS AND THEIR USES THEREOF - A compound, composition, method of synthesizing and using the compound of formula 1 are disclosed. The compound of formula I also comprises of salts, polymorphs, solvates, and hydrates thereof. The compound may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral, topical, transmucosal, inhalation, targeted delivery and sustained release formulations. Such compositions may be used to treat hepatic and genetic disorders related to copper overload. Multiple other compounds may be added with the instant claimed compounds and may be delivered as a pharmaceutical dose suitable for treating Wilson's disease. | 09-08-2011 |
| 20110237658 | COMPOUND AND METHOD FOR THE TREATMENT OF PAIN - The disclosure herein provides a compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications. | 09-29-2011 |
| 20110251268 | ANTIOXIDANT-CONTAINING FOOD COMPOSITION FOR USE IN INHIBITING HISTAMINE PATHWAYS IN COMPANION ANIMALS - The invention encompasses methods for inhibiting histamine release pathways in a companion animal, for example, felines and in treating or preventing idiopathic cystitis or interstitial cystitis. The compositions and methods of the invention include an amount of lipoic acid that is effective in inhibiting histamine release pathways in a companion animal, for example, felines and in treating or preventing idiopathic cystitis or interstitial cystitis. | 10-13-2011 |
| 20110269827 | USE OF LIPOIC ACID FOR TREATING OR PREVENTING DEGENERATIVE JOINT CONDITIONS, OSTEOARTHRITIS, CARTILAGE DAMAGE, AND RELATED DISORDERS IN COMPANION ANIMALS - The invention encompasses pet food compositions and uses thereof for the treatment and/or prevention of diseases or disorders in companion animals, for example, for the treatment or prevention of degenerative joint conditions, osteoarthritis, cartilage damage, and maintaining or increasing bone mineral density, wherein the compositions and uses include feeding a companion animal a composition including uses acid or a salt thereof. | 11-03-2011 |
| 20110269828 | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING WEIGHT-RELATED DISORDERS IN COMPANION ANIMALS - The invention encompasses compositions and methods for treating or preventing disorders in companion animals, wherein the compositions and methods include feeding the companion animal a composition including lipoic acid or a salt thereof. | 11-03-2011 |
| 20120004291 | COMPANION ANIMAL COMPOSITIONS INCLUDING PYRUVIC ACID AND SALTS THEREOF AND METHODS OF USE THEREOF - The invention encompasses pet food compositions and methods for the treatment and/or prevention of diseases or disorders in companion animals, for example, for the treatment or obesity, including administering a pet food composition including pyruvic acid or a salt thereof to a companion animal, or lipoic acid or salt thereof and pyruvic acid or a salt thereof to a companion animal. The invention encompasses pet food compositions and methods for managing weight including administering a pet food composition including pyruvic acid or a salt thereof, or lipoic acid or a salt thereof and pyruvic acid or a salt thereof to a companion animal to a companion animal. | 01-05-2012 |
| 20120022147 | 2, 6 XYLIDINE DERIVATIVES FOR THE TREATMENT OF PAIN - The disclosure herein provides a composition compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition to be used for treatment of pain. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications. The compound of formula 1 may also be offered as a kit. | 01-26-2012 |
| 20120035250 | PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING - Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia). | 02-09-2012 |
| 20120115939 | METHODS FOR USING LIPOIC ACID - The present provides methods for using lipoic acid. In one embodiment, the methods include administering lipoic acid to a female subject in need thereof, wherein at least 10 milligrams lipoic acid per kilogram of body weight is administered. In another embodiment, the methods include administering to a female subject in need thereof an effective amount of lipoic acid, wherein concentration of progesterone in the blood of the subject is increased compared to the subject prior to administration of the lipoic acid. The subject may be pregnant. | 05-10-2012 |
| 20120157515 | Methods and compositions for the treatment of "Burning Feet Syndrome" - Disclosed herein Methods and composition for the treatment of an individual with “Burning Feet Syndrome”. Included are the manner and process of making the composition, administration, uses, and effective therapeutic amounts of Pantothenic acid and Alpha-lipoic acid with no adverse side effects. The composition can be used to prophylax (prevent), treat acute or chronic symptoms caused by “Burning Feet Syndrome”. In combination with certain adjuvants, carriers, vehicles and delivery systems to improve the efficacy. | 06-21-2012 |
| 20120172421 | 2, 6 XYLIDINE DERIVATIVES FOR THE TREATMENT OF PAIN - The disclosure herein provides a compound of formula 1. The disclosure also provides a method of synthesizing the compound of formula 1. The compound of formula 1 or its pharmaceutical acceptable salts, as well as polymorphs, solvates, and hydrates thereof may be formulated as pharmaceutical composition. The pharmaceutical composition of compound of formula 1 or the final compound may be formulated for non-invasive peroral, topical (example transdermal), enteral, transmucosal, targeted delivery, sustained release delivery, delayed release, pulsed release and parenteral methods. Such compositions may be used to treat chronic pain manifested with chronic diseases or its associated complications. The compound may also be offered as a kit. | 07-05-2012 |
| 20120277294 | FUNCTIONAL FOOD ADDITIVES - Novel compounds, and in particular to diacylglycerol (1,3-DAG) and alpha-lipoic acid (LA) and/or dihydro-alpha-lipoic acid (DHLA) derivatives. In particular these novel compounds are used as functional food additives. These may for example be used as nutraceuticals and/or pharmaceuticals in the prevention and treatment of obesity, diabetes, atherosclerosis, oxidative stress and other lifestyle-related diseases. | 11-01-2012 |
| 20120283320 | STABLE, WATER-INSOLUBLE R-(+)-ALPHA-LIPOIC ACID SALT USEFUL FOR THE TREATMENT OF DIABETES MELLITUS AND ITS CO-MORBIDITIES - The present invention relates to oral nutritional and therapeutic products which are useful for preventing or treating compensated and decompensated insulin resistance and associated diseases and sequelae, or diabetes mellitus and its sequelae, complications, and co-morbidities, comprising magnesium R-(+)-alpha-lipoate. | 11-08-2012 |
| 20130041020 | Methods of Control and Prophylaxis of Inflammation and Mitigation of Inflammatory Conditions in Companion Animals - The invention relates to methods of control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in companion animals, e.g., dogs or cats, comprising administering a diet comprising lipoic acid. | 02-14-2013 |
| 20130096187 | PHARMACEUTICAL COMPOSITION FOR EXTERNAL USE - A pharmaceutical composition for external use, including: i) luliconazole represented by the following structural formula (1) and/or a salt thereof; and ii) crotamiton. | 04-18-2013 |
| 20130116312 | PLASMALOGEN COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND METHODS FOR TREATING DISEASES OF THE AGING - Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia). | 05-09-2013 |
| 20130281520 | Anti-Inflammatory And Antioxidant Conjugates Useful For Treating Metabolic Disorders - The present invention is directed to methods for treating metabolic disorders with compounds that are conjugates. The conjugates of the present invention are comprised of salicylic acid, triflusal, diflusinal, salsalate, IMD-0354, ibuprofen, diclofenac, licofelone, or HTB, and one or more antioxidants. | 10-24-2013 |
| 20130281521 | Methods and Compositions for the Prevention and Treatment of Kidney Disease - The invention provides compositions for preventing or treating kidney disease and improving kidney function comprising at least two ingredients selected from the group consisting of antioxidants and mitochondrial cofactors in amounts sufficient for preventing or treating kidney disease or for improving kidney function and methods for preventing and treating kidney disease or improving kidney function comprising administering such compositions to an animal susceptible to or suffering from kidney disease or impaired kidney function. In a preferred embodiment, the composition is admixed with one or more food ingredients to produce a food composition useful for preventing or treating kidney disease and improving kidney function, particularly in senior animals. | 10-24-2013 |
| 20140100267 | FUNCTIONAL FOOD ADDITIVES - Novel compounds, and in particular to diacylglycerol (1, 3-DAG) and alpha-lipoic acid (LA) and/or dihydro-alpha-lipoic acid (DHLA) derivatives. In particular these novel compounds are used as functional food additives. These may for example be used as nutraceuticals and/or pharmaceuticals in the prevention and treatment of obesity, diabetes, atherosclerosis, oxidative stress and other lifestyle-related diseases. | 04-10-2014 |
| 20140121266 | Choline Esters - Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage. | 05-01-2014 |
| 20140221467 | METFORMIN DERIVATIVES FOR TREATING DIABETES AND DIABETES COMPLICATIONS - The invention provides mutual ternary salts of metformin, lipoic acid and acidic amino acids such as aspartic acid and glutamic acid. The invention further provides treatment of prediabetes, diabetes, diabetic complications and/or other conditions in mammals in a method that comprises administering an effective amount of one or more of the foregoing compositions to a mammal in need of such treatment. | 08-07-2014 |
| 20140243400 | COMPOSITIONS COMPRISING CITRIC ACID AND MALIC ACID AND METHODS AND USES THEREOF - The invention relates to compositions comprising at least about 500 mg of citric acid; at least about 500 mg of malic acid; and at least about 100 mg of N-acetylcysteine, or at least about 100 mg of α-lipoic acid, or a mixture thereof and methods for use of the compositions thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. | 08-28-2014 |
| 20140309293 | CRYSTALLINE FORM - The invention concerns a new polymorphic form of R-(+)-α-lipoic acid and a process for the preparation thereof, in addition to the compositions that contain it and its use as a medicine or food supplement. | 10-16-2014 |
| 20140315989 | APOCYNIN-LIPOIC ACID CONJUGATES AND USES THEREOF - The present application relates to novel apocynin-lipoic acid covalent conjugates, compositions comprising these compounds and their use, in particular for the treatment of diseases, disorders or conditions that are mediated by oxidative stress. In particular, the present application includes compounds of Formula (I), and compositions and uses thereof. | 10-23-2014 |
| 20150038563 | STABLE COMPOSITION COMPRISING AN ANTI-AGEING COMPOUND AND A SOLVENT - A cosmetic composition including diacetylresveratryl thioctate and a solvent. The solvent has a | 02-05-2015 |
| 20150065564 | LIPOYL COMPOUNDS AND METHODS FOR TREATING ISCHEMIC INJURY - The present invention relates, in various embodiments, to a compound represented by Structural Formula (I), pharmaceutically acceptable salts or prodrugs thereof, and compositions comprising said compounds, or pharmaceutically acceptable salts or prodrugs thereof. Methods of using compounds of Structural Formulas (I) and (Ia) or compositions comprising compounds of Structural Formulas (I) and (Ia), or pharmaceutically acceptable salts or prodrugs thereof, to treat ischemia or ischemia-reperfusion injury are also disclosed. | 03-05-2015 |
| 20150087697 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUSCLE PAIN - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing muscle pain, a neurological disease, allergy, respiratory diseases or inflammatory disorder may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle disorders, muscle pain, spasticity, neuropathic pain, fibromyalgia, Parkinson's disease, allergy, chronic obstructive pulmonary disease, allergic rhinitis, headache, chronic pain, sub-chronic pain and local pain or its associated complications. | 03-26-2015 |
| 20150111959 | Choline Esters - Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage. | 04-23-2015 |
| 20150119452 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological conditions may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fibromyalgia, depression, neuropathic pain, severe pain, chronic pain, generalized pain, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, cancer pain, fibromyalgia and lower back pain. | 04-30-2015 |
| 20150119453 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing depression may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder (MDD), anxiety, neurological diseases, general anxiety disorder, social phobia, panic disorder, vasomotor symptoms, diabetic neuropathy, epilepsy, bipolar disorder, migraine, schizophrenia, cancer, menopause, HIV and familial adenomatous polyposis. | 04-30-2015 |
| 20150126591 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON'S DISEASE - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of Parkinson's disease may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be also used for the treatment of Huntington's disease, Alzheimer's disease, Multiple Sclerosis, Lateral Sclerosis, Neural Motor disorders. | 05-07-2015 |
| 20150126592 | METHODS OF TREATING OR PREVENTING DEGENERATIVE JOINT CONDITIONS, OSTEOARTHRITIS, CARTILAGE DAMAGE, AND RELATED DISORDERS IN COMPANION ANIMALS - The invention encompasses pet food compositions and methods for the treatment and/or prevention of diseases or disorders in companion animals, for example, for the treatment or prevention of degenerative joint conditions, osteoarthritis, cartilage damage, and maintaining or increasing bone mineral density, wherein the compositions and methods include feeding a companion animal a composition including lipoic acid or a salt thereof. | 05-07-2015 |
| 20150133533 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF COUGH - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing cough may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of acute respiratory tract infections, asthma, gout, fibromyalgia, facilitating conception, promotes secondary mucosal secretions in the respiratory system, muscle relaxant, allergy, asthma, chronic obstructive pulmonary disorders, spasms, respiratory and neurological diseases. | 05-14-2015 |
| 20150141500 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of depressive disorders, anxiety disorders, attention deficit hyperactivity disorder, migraine prophylaxis, eating disorders, bipolar disorder, post-herpetic neuralgia, insomnia, ankylosing spondylitis, recurring biliary dyskinesia, nocturnal enuresis, cyclic vomiting syndrome, post-traumatic stress disorder (PTSD) and neuropathy. | 05-21-2015 |
| 20150297561 | Low Dose Lipoic Acid Pharmaceutical Compositions and Methods - Compositions containing low doses of lipoic acid-based active agents and methods for using the same are provided. In particular, compositions containing low dose lipoic acid, lipoic acid derivatives, said lipoic acid seleno-derivatives and are provided to prevent and/or treat ocular diseases. | 10-22-2015 |
| 20150353522 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MODERATE TO SEVERE PAIN - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I; and methods for treating or preventing moderate to severe pain, may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of muscle pain, spasticity, neuropathic pain, fibromyalgia, post-operative pain, muscle spasticity, headache, chronic pain, sub-chronic pain and local pain. | 12-10-2015 |
| 20150359780 | Compositions for Improved Body Composition - A nutritional supplement is provided comprising alpha-lipoic acid and curcumin. The nutritional supplement may be used for reducing weight or reducing weight gain, for reducing fat or reducing fat gain, for reducing loss in lean mass or maintaining lean mass, or for reducing loss of appetite or for maintaining appetite. | 12-17-2015 |
| 20160122282 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing neurological disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, migraine, schizophrenia, depression, Alzheimer's disease, cancer, HIV and familial adenomatous polyposis. | 05-05-2016 |
| 20160122313 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DIABETES - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing diabetes may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of metabolic syndrome, insulin resistance, glucose intolerance, hyperinsulinemia, diabetes mellitus, diabetes insipidus, hyperglycemia and diabetic complications. | 05-05-2016 |
| 20160200703 | NOVEL AND SPECIFIC INHIBITORS OF CYTOCHROME P450 26 RETINOIC ACID HYDROXYLASE | 07-14-2016 |
| 20170231951 | DITHIOL COMPOUNDS, DERIVATIVES, AND USES THEREFOR | 08-17-2017 |
| 514441000 | Chalcogen bonded directly to ring carbon of the hetero ring | 4 |
| 20090036516 | COMPOUNDS FOR TREATING METABOLIC SYNDROME - Compounds of general formula: | 02-05-2009 |
| 20090215881 | Polyphenolic Bioprecursors - Cosmetic and therapeutic, in particular dermatological bioprecursors have the formula [A] | 08-27-2009 |
| 20100168216 | PROSTAGLANDIN PHARMACEUTICAL COMPOSITIONS - The present invention relates to new prostaglandin derivatives having improved pharmacological activity and enhanced tolerability. They can be employed for the treatment of glaucoma and ocular hypertension. | 07-01-2010 |
| 20100261783 | CRUCIFEROUS 3H-1,2-DITHIOLE-3-THIONE (D3T) AND METHODS OF PROTECTING AGAINST CELL INJURY - Astrocytes possess important roles in maintaining normal brain function and providing trophic support to the neurons. They also suffer a range of toxic insults, being a chief target of prooxidants such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), 1-methyl-4-phenylpyridinium (MPP+), 6-hydroxydopamine (6-OHDA), 4-hydroxy-2-nonenal (HNE), and acrolein. Recently, we have observed that the cellular antioxidants and phase 2 enzymes can be upregulated by 3H-1,2-dithiole-3-thione (D3T), a nutraceutical found in cruciferous vegetables, against many prooxidants in human neuroblastoma cell lines (SH-SY5Y). However, the regulation of the above cellular factors by D3T in astrocytes and their role in ameliorating the neurotoxic effects of the above neurotoxins have not been investigated. In this study, we show that incubation of human primary astrocytes with micromolar concentrations (5-100 IM) of D3T for 24 h resulted in significant increases in the levels of reduced glutathione (GSH), glutathione reductase (GR), and the phase 2 enzyme NAD(P)H:quinone oxidoreductase 1 (NQO1). D3T treatment also caused time-dependent increases in mRNA expression of the gamma-glutamylcysteine ligase catalytic subunit (GCLC), GR, and of NQO1 in these cells. Pretreatment of astrocytes with D3T was found to afford remarkable protection against the neurocytotoxicity elicited by MPTP, MPP+, 6-OHDA, HNE and acrolein. Taken together, this study demonstrates for the first time that in human astrocytes, the cruciferous nutraceutical D3T potently induces the cellular GSH system and the phase 2 enzyme NQO1, which is accompanied by dramatically increased resistance of these cells to the damage induced by various neurotoxicants. The results of this study may have important implications for the development of novel neuroprotective strategies. | 10-14-2010 |
